Cronos Group Inc. 8K

Cronos Group Inc. reported record Q2 2026 financial results, ongoing share repurchases, progress toward closing its CanAdelaar acquisition, and the initiation of a new Israeli anti-dumping investigation into Canadian medical cannabis imports.

On August 6, 2026, Cronos Group Inc. reported strong second quarter 2026 results, highlighting record net revenue of $53.0 million (up 58% year-over-year, 51% on an organic constant-currency basis), record gross profit and Adjusted EBITDA of $13.1 million, and a swing to net income of $35.7 million from a prior-year loss, driven by higher cannabis flower and extract sales in Canada, Israel, and Germany and favorable mix with no excise taxes in certain markets; the company also disclosed having repurchased 12.3 million shares in the first half of 2026, provided updates on its pending acquisition of Dutch company CanAdelaar B.V. expected to close in the second half of 2026, and described a new anti-dumping investigation initiated by the Israel Ministry of Economy and Industry concerning Canadian medical cannabis imports, which Cronos disputes but cannot yet predict the outcome or potential duties or import restrictions.

Filing Facts

CIK

1656472

Ticker

-

Form

8K

Source Type

sec

Accession

0001656472-26-000050

Alert Tier

7